Fig. 3From: The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysisComparison of disease progression rate. a Combination therapy vs. TACE. b Combination therapy vs. sorafenibBack to article page